{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-031105","form_type":"8-K","ticker":"INBS","cik":"0001725430","company_name":"INTELLIGENT BIO SOLUTIONS INC.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.896885+00:00","generated_at":"2026-06-22T01:37:22.838422+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Intelligent Bio Solutions acquires IFP, reports Q1 net loss of $1.21M, cash $5.74M","bullets":["Acquired Intelligent Fingerprinting Limited (IFP) for its sweat-based fingerprint drug screening technology.","Net loss $1.21M ($0.08 per share) vs $1.43M ($0.10) prior year; cash $5.74M as of Sept 30, 2022.","New customer wins: Goldstar Transport, Eastern Airways, and Glass Systems Group adopted IFP drug test.","Board additions: David Jenkins (CEO of Catheter Precision) and Jason Isenberg appointed in October.","Cash runway expected into first half of calendar 2023; excludes potential new market revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-031105","json":"https://secwatch.observer/filing/0001493152-22-031105.json","markdown":"https://secwatch.observer/filing/0001493152-22-031105.md","text":"https://secwatch.observer/filing/0001493152-22-031105.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725430/000149315222031105/0001493152-22-031105-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725430/000149315222031105/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:37:22.838422+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"729f69f5d270b8327c8c79e12cdb9aca61b26e8e","claim":"INTELLIGENT BIO SOLUTIONS INC. reported preliminary financial results for first financial quarter ended September 30, 2022.","evidence_excerpt":"On November 9, 2022, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”) announcing financial results for the three months ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725430/000149315222031105/0001493152-22-031105-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first financial quarter ended September 30, 2022"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}